E!115695, ARCHER, Tada Medical AB

Purpose and goal: AM-ReLink is a combination of two ground-breaking innovations in widely different fields.

The goal achieved during the course of the project is to develop AM-ReLink as a basis for a product family of self-cleaning safety connectors to prevent the loss of venous catheters through dislodgement accidents, patient injury and HAI (healthcare-associated infections) in patients undergoing infusion therapy. The product is now ready for the clinical phase.

Expected results and effects:

Infusion therapy is the most common invasive treatment in modern healthcare. Unfortunately, up to 36% of treatments are interrupted due to the catheter accidentally being torn from the patient´s vein. This leads to patient injury, increased plastic waste, leakage of medicines and increased risk of care-related infections.

Based on the estimated cost to AM-ReLink and our sales forecast, the introduction of our product would result in a cumulative cost saving for the EU and our customers in Europe and the US of €2.1 billion. Approach and implementation:

Project ARCHER has been implemented as six work packages. WP 1: Product system specification. WP 2: Coating procedure maturation. WP 3: Connector maturation. WP 4: Pre-clinical documentation. WP 5: Dissemination and exploitation. Och WP 6: Project management. The project has lasted over 28 months, and the work has been evenly distributed between a Swedish and a Norwegian party who together represent the entire consortium.